Thymosin Alpha 1

@article{Garaci2007ThymosinA1,
  title={Thymosin Alpha 1},
  author={Enrico Garaci and Cartesio Favalli and Francesca Pica and Paola Sinibaldi Vallebona and Anna Teresa Palamara and Claudia Matteucci and Pasquale Pierimarchi and Annalucia Serafino and Antonio Mastino and Francesco Bistoni and Luigina Romani and Guido Rasi},
  journal={Annals of the New York Academy of Sciences},
  year={2007},
  volume={1112}
}
Abstract:  After the initial dramatic effects, observed in a Lewis lung carcinoma animal model, using a combination of thymosin alpha 1 (Tα1) and interferon (IFN) after cyclophosphamide, a number of other preclinical models in mice (Friend erythroleukemia and B16 melanoma) and in rats (DHD/K12 colorectal cancer liver metastasis) have confirmed the efficacy of the combination therapy with Tα1 and either IFN or IL‐2 plus chemotherapy. These results provided the scientific foundation for the first… Expand
Historical review on thymosin α1 in oncology: preclinical and clinical experiences
TLDR
The historical background of T α1 use in oncology is reviewed, aiming to highlight the importance of Tα1 as an immunotherapeutic tool to be used in combination with chemotherapy, a concept that is not yet fully established in clinic. Expand
Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis
TLDR
These initial pilot studies support the hypothesis that immune-suppressive indications, including sepsis and melanoma, may be treated with Ta1 alone or by Ta1 in combination with other immunotherapies. Expand
From lab to bedside: emerging clinical applications of thymosin α1
TLDR
The most recent reports of clinical trials with Tα1 are pointing to important, hitherto unrecognized, applications in a number of diseases and disorders, including septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, TB, severe acute respiratory syndrome, and lung infections in critically ill patients. Expand
Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial
TLDR
In this phase III trial, there is no evidence of any benefit to thymostimulin in the treatment of advanced HCC and there is therefore no justification for its use as single-agent treatment. Expand
Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration.
TLDR
The Tα1-transformed B. longum promotes thymus and lymph nodes growth, stimulates T cell proliferation and maturation, and enhances cellular immunity through Th1 pathway by oral administration. Expand
Serum thymosin alpha 1 levels in normal and pathological conditions
TLDR
Evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. Expand
Thymosin alpha 1 and HIV-1: recent advances and future perspectives.
TLDR
The present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection and recent findings and future perspectives of therapeutic intervention are reported. Expand
Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application
TLDR
A possible therapeutic application in MS for Tα1 and Tβ4 alone or combined with other approved drugs may be envisaged, and what is known in this field on the roles of thymosin- α1 and -β4 as potential anti-inflammatory as well as neuroprotective and remyelinating molecules and their mechanisms of action is described. Expand
Effect of a C-end rule modification on antitumor activity of thymosin α1.
TLDR
Tα1-RGDR treatment led to significant inhibition of tumor growth at a dose at which Tα1 showed a slight effect in the B16F10 tumor growth model, and the better therapeutic effects after treatment with T α1- RGDR compared with Talpha1. Expand
A Tumor-Penetrating Peptide Modification Enhances the Antitumor Activity of Thymosin Alpha 1
TLDR
The findings indicated that the addition of an iRGD fragment increased the anti-proliferative activity of T α1 against cancer cells by improving the ability of Tα1 to penetrate the tumor cells. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 37 REFERENCES
Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice
TLDR
The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Expand
Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer.
TLDR
The main data supporting a pivotal role of Talpha 1 in combination therapy consisting of the use of chemotherapeutic agents associated with thymosin alpha 1 (Talpha 1) and different cytokines are reviewed. Expand
Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer
TLDR
The main data supporting a pivotal role of Tα 1 in such combination protocols are reviewed and special mention of the molecular mechanisms underlying the effects of T α 1 on immune effector cells as well as on target tumour cells are provided. Expand
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
TLDR
High doses of T alpha 1 improve anti-tumour efficacy of tnple chemo-immunotherapy against B16 melanoma, and appear to be mediated by stimulation of the host immune response. Expand
Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
TLDR
The antitumor action of these combined chemoimmunotherapy protocols seems to involve activation of the immune response since a synergistic increase of the cytotoxicity of spleen cells was demonstrated in treated mice and a high lymphoid cell infiltration was found at the tumor site and in the livers of treated mice. Expand
Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-αl and interferon-α2a
TLDR
The combination of DDP and VP-16 and TA1 and IFN is effective in advanced NSCLC with acceptable toxicity, however, the results of this study need to be confirmed in a randomised trial. Expand
Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.
TLDR
The combination of DDP and VP-16 and TA1 and IFN is effective in advanced NSCLC with acceptable toxicity, however, the results of this study need to be confirmed in a randomised trial. Expand
The efficacy and safety of thymosin alpha‐1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial
TLDR
Tα1 at doses of 0.8 and 1.6 mg exhibits long‐term efficacy against hepatitis B with a good safety profile, and is likely related to the positive immune effects caused by the response to Tα1 treatment. Expand
Anti‐tumor effect of combined treatment with thymosin alpha 1 and interleukin‐2 after 5‐fluorouracil in liver metastases from colorectal cancer in rats
TLDR
Combined chemo‐immunotherapy was shown both to significantly reduce the growth of liver metastases and to prevent extra‐hepatic spread and 5‐FU/Tαl/IL‐2 also improved survival rate. Expand
Combination low‐dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B
TLDR
Combination low‐dose lymphoblastoid IFN‐α and Tα1 treatment may provide a safe and potentially effective therapeutic approach in chronic hepatitis B and require confirmation in future randomized controlled studies. Expand
...
1
2
3
4
...